Alnylam Pharmaceuticals Press Release | Sep 29, 2024 | Alnylam ...
WEBSep 29, 2024 — Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Is Expected To …
WEB2 days ago — Consensus from 30 of the American Biotechs analysts is that Alnylam Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating ...
Press Releases - Alnylam Pharmaceuticals, Inc.
WEBAlnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Alnylam Pharma’s Promising Clinical Data Tempered by Market …
WEB6 days ago — The positive echocardiogram and biomarker data from the HELIOS-B study indicate that Alnylam’s drug vutrisiran shows significant benefits for patients with cardiac amyloidosis, particularly in...
Alnylam® Newsroom
WEBRNAi RNAi Therapeutics, from Possibility to Patients. Careers & Culture Alnylam Named a Best Workplace for Innovators for the 4th Year in a Row by Fast Company. Responsibility Alnylam Named a Humankind 100 Company for the 3rd Year in a Row. Press Releases Noteworthy announcements from Alnylam.
Alnylam Pharmaceuticals, Inc. (ALNY) Latest Stock News
WEBGet the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock news and headlines to help you in your trading and investing decisions.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year …
WEBFeb 15, 2024 — ALNY. − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 –. − Company...
Articles | Alnylam® Newsroom
WEBApr 16, 2024 — December 19, 2023 Community Spotlight: GenUnity – A Community-Based Model of Change Through Alnylam Challengers, Alnylam partners with organizations like GenUnity which works to unlock community-centered innovation Read More ›
Alnylam Reports Additional Positive Interim Phase 1 Results for …
WEBOct 25, 2023 — CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase...
Alnylam's drug cuts risk of death, heart issues in key study, shares ...
WEBJune 24 (Reuters) - Alnylam Pharmaceuticals (ALNY.O) said its drug vutrisiran reduced deaths and cardiovascular events by a third in a study involving patients with a rare heart disease, sending...